Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Otr Acquisition Corp Cl A (OTRA)

Otr Acquisition Corp Cl A (OTRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 125,609
  • Shares Outstanding, K 12,675
  • Annual Sales, $ 0 K
  • Annual Income, $ 4,690 K
  • 60-Month Beta -0.07
  • Price/Sales N/A
  • Price/Cash Flow 26.80
  • Price/Book N/A
Trade OTRA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.08 +22.65%
on 05/13/22
15.30 -35.23%
on 05/10/22
-0.33 (-3.22%)
since 04/19/22
3-Month
8.08 +22.65%
on 05/13/22
15.30 -35.23%
on 05/10/22
-0.27 (-2.65%)
since 02/18/22
52-Week
8.08 +22.65%
on 05/13/22
15.30 -35.23%
on 05/10/22
-0.09 (-0.90%)
since 05/19/21

Most Recent Stories

More News
Comera Life Sciences Debuts as Publicly Traded Company Focused on Transforming Biologics

Comera Life Sciences Holdings, Inc. (“Comera” or the “Company”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today...

OTRAU : 9.55 (-17.24%)
OTRAW : 0.3930 (-2.14%)
OTRA : 9.91 (-11.75%)
Comera Life Sciences Announces Research Collaboration with Top 10 Pharmaceutical Company to Develop Subcutaneous Formulation

Comera Life Sciences, Inc. (“Comera” or the “Company”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced...

OTRA : 9.91 (-11.75%)
Comera Life Sciences to Present at 18th Annual PEGS Boston Conference & Expo

Comera Life Sciences, Inc. , which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that Robert P. Mahoney, Ph.D.,...

OTRA : 9.91 (-11.75%)
Comera Life Sciences and Intas Pharmaceuticals Announce Research Collaboration

Today, Comera Life Sciences, Inc. (“Comera” or the “Company”) and Intas Pharmaceuticals Ltd. (“Intas”) announced a research collaboration to develop a new generation of bio-innovative biologic...

OTRA : 9.91 (-11.75%)
Comera Life Sciences and OTR Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination

Comera Life Sciences, Inc. (“Comera”) , which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp. (Nasdaq:...

OTRAU : 9.55 (-17.24%)
OTRAW : 0.3930 (-2.14%)
OTRA : 9.91 (-11.75%)
OTR Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination

OTR Acquisition Corp. (Nasdaq: OTRAU, OTRA and OTRAW), a publicly traded special purpose acquisition company (SPAC), today announced the confidential submission with the U.S. Securities and Exchange Commission...

OTRA : 9.91 (-11.75%)
Comera Life Sciences to Become Publicly Traded via Business Combination with OTR Acquisition Corp.

Comera Life Sciences, Inc. (“Comera” or the “Company”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition...

OTRAU : 9.55 (-17.24%)
OTRAW : 0.3930 (-2.14%)
OTRA : 9.91 (-11.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 13.73
2nd Resistance Point 12.42
1st Resistance Point 11.16
Last Price 9.91
1st Support Level 8.59
2nd Support Level 7.28
3rd Support Level 6.02

See More

52-Week High 15.30
Fibonacci 61.8% 12.54
Fibonacci 50% 11.69
Fibonacci 38.2% 10.84
Last Price 9.91
52-Week Low 8.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar